Detalhe da pesquisa
1.
Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review.
BMC Musculoskelet Disord
; 24(1): 751, 2023 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37740174
2.
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
Amyloid
; 31(1): 1-11, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37469249
3.
Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study.
Neurol Ther
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38512694
4.
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
Amyloid
; 30(1): 49-58, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36120830
5.
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Neurol Ther
; 12(5): 1759-1775, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523143
6.
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
Neurology
; 96(3): e412-e422, 2021 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33087494
7.
Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry.
Sci Rep
; 11(1): 11645, 2021 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34079032
8.
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Lancet Neurol
; 20(1): 49-59, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33212063
9.
Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank.
Amyloid
; 27(3): 184-190, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32425064
10.
Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
J Neurol
; 267(3): 713-714, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32030522
11.
Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
J Neurol
; 267(3): 703-712, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31728713
12.
Neurofilament light chain as a biomarker for monitoring response to change in treatment in hereditary ATTR amyloidosis.
Amyloid
; 30(3): 351-352, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36908191
13.
Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe.
J Dermatolog Treat
; 29(1): 8-12, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28506134
14.
Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia: Results from Patient and Physician Surveys.
Adv Ther
; 34(6): 1426-1437, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28502036
15.
TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey.
J Dermatol
; 43(3): 298-304, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26365805